Non-peptide
Raloxifene
Also known as
Evista · ralox · raloxifene 60 mg · gyno SERM
Community talk. May contain inaccuracies. Not medical advice. Not a protocol. Not for human or animal use.
What it is
| Evista or ralox | Raloxifene is an oral selective estrogen-receptor modulator, or SERM. Bodybuilding discussion centers on breast lumps, tenderness and puffy nipples grouped as gyno. |
|---|---|
| SERM versus AI | It changes estrogen's action at receptors rather than stopping estrogen production. Gyno treatment and post-cycle hormone recovery are different goals; the tamoxifen comparison is community shorthand. |
Notes
Raloxifene, also called Evista or ralox, is an oral selective estrogen-receptor modulator (SERM). Bodybuilding discussions focus on gyno: breast lumps, tenderness and puffy nipples. Accounts range from noticeable improvement to no change or worsening, and an improvement while taking it may not last after stopping.
Tablets, not a peptide injection. The discussion concerns oral tablets, commonly described as 60 mg. They require no reconstitution. A puffy appearance, a painful nipple and a palpable lump are different things that posters may group together as gyno. Raloxifene — S1ngleBarre1 and visible replies (Personal report · Accessed 2026-09-30) · Raloxifene gyno — Cultural-Can-3394 (Personal report · Accessed 2026-09-30)
It changes estrogen's action at receptors. A SERM can block estrogen signals in some tissues and support them in others. Raloxifene's breast effects explain the gyno interest; it is not an aromatase inhibitor (AI) that prevents estrogen production. Raloxifene hydrochloride tablets — DailyMed prescribing information (Official context · Accessed 2026-09-30)
Gyno treatment and PCT are different goals. Post-cycle therapy (PCT) means attempts to recover hormone function after anabolic steroids. The familiar ralox-for-gyno, tamoxifen-for-PCT comparison is community shorthand, not proof that raloxifene substitutes for a complete recovery assessment. Tamoxifen is also called Nolvadex or nolva. My experience with Tamoxifen vs Raloxifene for pubertal gyno (Community discussion · Accessed 2026-09-30)
Source context — Raloxifene — S1ngleBarre1 and visible replies: Subjective estimates, steroid history, planned rather than completed course; no completed stopping outcome in inspected replies. No sourcing details reproduced.
Source context — Raloxifene gyno — Cultural-Can-3394: Two-week snapshot, subjective size estimate, previous anabolic cycles; residual sensitivity; tablet identity and amount unverified.
Source context — Raloxifene hydrochloride tablets — DailyMed prescribing information: Official label context; risks and Table 3 population are predominantly postmenopausal women. Not community doses, proof of male gyno response or a male individualized risk estimate. All label mirrors/reprints belong to this one source origin; prose allocation recorded below.
Source context — My experience with Tamoxifen vs Raloxifene for pubertal gyno: OP has pubertal gyno while commenter describes newer steroid-associated episodes. Supplier uncertainty unverified. Different authors cannot be pooled into a success rate. Advice in replies is not endorsed.
What people notice
| Smaller-feeling lumps or less puffiness | Some report improvement by two weeks or day 26. One still had sensitivity despite a smaller-feeling lump; touch, appearance and discomfort can change differently. |
|---|---|
| No change or worsening | One account describes no benefit after three months. Another reports increasing puffiness during use and clearer worsening after stopping. |
Notes
Less puffiness and a smaller-feeling lump. S1ngleBarre1 described much smaller lumps and almost no puffiness by day 26, despite an eight-year history after steroid use. Their estimate of roughly 75% reduction was personal judgment, not a scan or measured gland volume. Raloxifene — S1ngleBarre1 and visible replies (Personal report · Accessed 2026-09-30)
Appearance and tenderness can move differently. Cultural-Can-3394 described a smaller left-sided lump after two weeks at 120 mg/day, but continued sensitivity. Relief of one feature does not establish that the whole problem has resolved. Raloxifene gyno — Cultural-Can-3394 (Personal report · Accessed 2026-09-30)
Months can pass without a noticeable response. sheker_03 felt neither benefit nor side effects after three months. Older discussion also describes no noticeable feeling or mood and hot-flash complaints during weeks 1–4. Feeling a drug is not evidence that a lump is shrinking. My gyno experience: Raloxifene did not work, on Tamoxifen for 1 month — sheker_03 (Personal report · Accessed 2026-09-30)
Worsening is part of the record too. hellloitsme69 felt nipple activity but saw more puffiness while taking raloxifene, then worsening after stopping and improvement after returning to tamoxifen. They questioned product quality and individual response. Neither explanation was verified, and feeling activity was not an early success signal. My experience with Tamoxifen vs Raloxifene for pubertal gyno (Community discussion · Accessed 2026-09-30)
Source context — Raloxifene — S1ngleBarre1 and visible replies: Subjective estimates, steroid history, planned rather than completed course; no completed stopping outcome in inspected replies. No sourcing details reproduced.
Source context — Raloxifene gyno — Cultural-Can-3394: Two-week snapshot, subjective size estimate, previous anabolic cycles; residual sensitivity; tablet identity and amount unverified.
Source context — My gyno experience: Raloxifene did not work, on Tamoxifen for 1 month — sheker_03: One account; bupropion discontinued with tamoxifen initiation. Later improvements and stopping outcome belong to tamoxifen, not raloxifene. No causal comparison.
Source context — My experience with Tamoxifen vs Raloxifene for pubertal gyno: OP has pubertal gyno while commenter describes newer steroid-associated episodes. Supplier uncertainty unverified. Different authors cannot be pooled into a success rate. Advice in replies is not endorsed.
Doses people talk about
| Recurring oral amount | 60 mg/day appears in both an improvement account and an unsuccessful account. Tablet strength and total daily amount are separate concepts. |
|---|---|
| Other amounts | One positive poster planned a later reduction to 30 mg/day; another reports 120 mg/day for two weeks. These separate accounts do not establish an escalation rule. |
Notes
60 mg/day orally is a recurring amount. It appears in both the improvement account and the unsuccessful pubertal-gyno account. Daily total and tablet strength are separate concepts; the same reported amount produced different experiences. Raloxifene — S1ngleBarre1 and visible replies (Personal report · Accessed 2026-09-30) · My experience with Tamoxifen vs Raloxifene for pubertal gyno (Community discussion · Accessed 2026-09-30)
30 mg reductions and 120 mg/day also appear. The positive poster planned a later 30 mg/day reduction. A separate account reported 120 mg/day for two weeks. Older notes mention splitting and 60–120 mg amounts without a clear interval; those ambiguous mentions do not establish 120 mg per administration or an escalation rule. Raloxifene — S1ngleBarre1 and visible replies (Personal report · Accessed 2026-09-30) · Raloxifene gyno — Cultural-Can-3394 (Personal report · Accessed 2026-09-30)
Source context — Raloxifene — S1ngleBarre1 and visible replies: Subjective estimates, steroid history, planned rather than completed course; no completed stopping outcome in inspected replies. No sourcing details reproduced.
Source context — My experience with Tamoxifen vs Raloxifene for pubertal gyno: OP has pubertal gyno while commenter describes newer steroid-associated episodes. Supplier uncertainty unverified. Different authors cannot be pooled into a success rate. Advice in replies is not endorsed.
Source context — Raloxifene gyno — Cultural-Can-3394: Two-week snapshot, subjective size estimate, previous anabolic cycles; residual sensitivity; tablet identity and amount unverified.
Half-life, onset & duration
| Noticeable change | Checkpoints range from one-sided change by day four to two weeks or day 26. There is no dependable onset day. |
|---|---|
| Effect duration | No single-tablet window is established. One person reports worsening a week off; another still reports improvement two months off. Neither defines a typical or permanent result. |
| Half-life | The saved label gives means of 27.7 hours after a single dose and 32.5 hours with repeated dosing in healthy postmenopausal women. These are blood measurements, not male gyno-effect durations. |
Notes
Some report changes within days or weeks. A reply in the positive thread described one side improving by day four while the other lagged. The main author reported improvement by day 26; the 120 mg/day account reported a change by two weeks. These are report checkpoints, not a guaranteed starting day. Raloxifene — S1ngleBarre1 and visible replies (Personal report · Accessed 2026-09-30) · Raloxifene gyno — Cultural-Can-3394 (Personal report · Accessed 2026-09-30)
Months can pass without a noticeable response. sheker_03 felt neither benefit nor side effects after three months. Older discussion also describes no noticeable feeling or mood and hot-flash complaints during weeks 1–4. Feeling a drug is not evidence that a lump is shrinking. My gyno experience: Raloxifene did not work, on Tamoxifen for 1 month — sheker_03 (Personal report · Accessed 2026-09-30)
No predictable single-tablet effect window. Posts track breast appearance across repeated use, rather than an hours-long felt effect. They do not establish how long one tablet controls tenderness or growth. Raloxifene — S1ngleBarre1 and visible replies (Personal report · Accessed 2026-09-30) · My gyno experience: Raloxifene did not work, on Tamoxifen for 1 month — sheker_03 (Personal report · Accessed 2026-09-30)
Worsening after a week off. hellloitsme69 described clearer worsening after stopping, following increased puffiness during use. This does not establish a typical recurrence window. My experience with Tamoxifen vs Raloxifene for pubertal gyno (Community discussion · Accessed 2026-09-30)
Improvement still present two months off. That was RoidyNoob's follow-up snapshot, not permanent reversal. Raloxifene & Gyno. My experience. Log — RoidyNoob (Personal report · Accessed 2026-09-30)
Label half-life: 27.7 hours after a single dose; 32.5 hours with repeated dosing. These means come from pharmacokinetic data in healthy postmenopausal women, not community measurements or a gyno-effect duration. The approved 60 mg/day indications concern postmenopausal osteoporosis and breast-cancer risk reduction, not male gyno. Raloxifene hydrochloride tablets — DailyMed prescribing information (Official context · Accessed 2026-09-30)
Source context — Raloxifene — S1ngleBarre1 and visible replies: Subjective estimates, steroid history, planned rather than completed course; no completed stopping outcome in inspected replies. No sourcing details reproduced.
Source context — Raloxifene gyno — Cultural-Can-3394: Two-week snapshot, subjective size estimate, previous anabolic cycles; residual sensitivity; tablet identity and amount unverified.
Source context — My gyno experience: Raloxifene did not work, on Tamoxifen for 1 month — sheker_03: One account; bupropion discontinued with tamoxifen initiation. Later improvements and stopping outcome belong to tamoxifen, not raloxifene. No causal comparison.
Source context — My experience with Tamoxifen vs Raloxifene for pubertal gyno: OP has pubertal gyno while commenter describes newer steroid-associated episodes. Supplier uncertainty unverified. Different authors cannot be pooled into a success rate. Advice in replies is not endorsed.
Source context — Raloxifene & Gyno. My experience. Log — RoidyNoob: One retrospective account following anabolic steroids and other PCT drugs; subjective improvement. Quoted duplicates are the same author, not corroboration. Later page 4 retrieval failed, so no later durability is claimed. Source family is this original forum post.
Source context — Raloxifene hydrochloride tablets — DailyMed prescribing information: Official label context; risks and Table 3 population are predominantly postmenopausal women. Not community doses, proof of male gyno response or a male individualized risk estimate. All label mirrors/reprints belong to this one source origin; prose allocation recorded below.
Cycles people discuss
| Weeks to months | One poster planned 55 days at 60 mg/day then ten days at 30 mg/day, without a documented completed outcome. Other histories describe three months without response or a six-month course. |
|---|---|
| Breaks and tapering | No repeat calendar, required break or taper that reliably prevents recurrence is established in the stopping accounts. |
Notes
Weeks to months, with no agreed course. The positive poster planned 55 days at 60 mg/day followed by ten days at 30 mg/day; a finished outcome was not documented. The nonresponder had already taken it for three months. Raloxifene — S1ngleBarre1 and visible replies (Personal report · Accessed 2026-09-30) · My gyno experience: Raloxifene did not work, on Tamoxifen for 1 month — sheker_03 (Personal report · Accessed 2026-09-30)
Six months is another history, not a minimum. That was RoidyNoob's reported course. Raloxifene & Gyno. My experience. Log — RoidyNoob (Personal report · Accessed 2026-09-30)
No established repeat calendar or protective taper. Stopping accounts do not establish a required break or dependable rebound-prevention method. The weeks-long folklore is not a lifelong maintenance claim. My experience with Tamoxifen vs Raloxifene for pubertal gyno (Community discussion · Accessed 2026-09-30)
Source context — Raloxifene — S1ngleBarre1 and visible replies: Subjective estimates, steroid history, planned rather than completed course; no completed stopping outcome in inspected replies. No sourcing details reproduced.
Source context — My gyno experience: Raloxifene did not work, on Tamoxifen for 1 month — sheker_03: One account; bupropion discontinued with tamoxifen initiation. Later improvements and stopping outcome belong to tamoxifen, not raloxifene. No causal comparison.
Source context — Raloxifene & Gyno. My experience. Log — RoidyNoob: One retrospective account following anabolic steroids and other PCT drugs; subjective improvement. Quoted duplicates are the same author, not corroboration. Later page 4 retrieval failed, so no later durability is claimed. Source family is this original forum post.
Source context — My experience with Tamoxifen vs Raloxifene for pubertal gyno: OP has pubertal gyno while commenter describes newer steroid-associated episodes. Supplier uncertainty unverified. Different authors cannot be pooled into a success rate. Advice in replies is not endorsed.
Stacks
| PCT combinations | hCG and enclomiphene occur in post-cycle combinations; heavy aromatase-inhibitor use adds another hormone change. These accounts cannot isolate raloxifene's contribution. |
|---|---|
| Tamoxifen comparison | Tamoxifen is mainly compared or switched to. A later tamoxifen result after raloxifene failed is not a durable raloxifene result or proof of a combined benefit. |
Notes
Other medicines complicate interpretation. hCG and enclomiphene occur in PCT combinations, while heavy AI use adds another hormone change. Such combinations cannot isolate raloxifene's contribution.
Other hormone medicines: hCG and enclomiphene occur in post-cycle combinations; aromatase inhibitors add another hormone change. These co-mentions do not establish a useful or protective combination. [community]
Gyno treatment and PCT are different goals. Post-cycle therapy (PCT) means attempts to recover hormone function after anabolic steroids. The familiar ralox-for-gyno, tamoxifen-for-PCT comparison is community shorthand, not proof that raloxifene substitutes for a complete recovery assessment. Tamoxifen is also called Nolvadex or nolva. My experience with Tamoxifen vs Raloxifene for pubertal gyno (Community discussion · Accessed 2026-09-30)
A switch is not a controlled comparison. After three months without a raloxifene response, sheker_03 reported improvement on tamoxifen alongside severe low mood, fatigue and poor concentration. Stopping bupropion occurred at the same time. Later replies describe better tolerance after reducing tamoxifen and no returning growth one month after stopping it; these are tamoxifen follow-ups, not durable raloxifene results. My gyno experience: Raloxifene did not work, on Tamoxifen for 1 month — sheker_03 (Personal report · Accessed 2026-09-30)
Tamoxifen comparisons and switches: These concern different drugs and goals. Later tamoxifen improvement is not a persistent raloxifene benefit or proof that combining them works. [community]
Source context — My experience with Tamoxifen vs Raloxifene for pubertal gyno: OP has pubertal gyno while commenter describes newer steroid-associated episodes. Supplier uncertainty unverified. Different authors cannot be pooled into a success rate. Advice in replies is not endorsed.
Source context — My gyno experience: Raloxifene did not work, on Tamoxifen for 1 month — sheker_03: One account; bupropion discontinued with tamoxifen initiation. Later improvements and stopping outcome belong to tamoxifen, not raloxifene. No causal comparison.
Watch for
| Clot and stroke warnings | The saved label warns about clots, particularly with immobility, and fatal stroke in susceptible postmenopausal women. That population does not provide a personal risk estimate for male use. |
|---|---|
| Reported rashes and unwanted feelings | One person describes foot rashes persisting but fading after stopping. Older accounts also include mood and hot-flash complaints. |
| Restrictions and medicines | The label contraindicates prior clots and pregnancy, lists no male indication, and calls for interaction review with warfarin, cholestyramine and systemic estrogen. |
Notes
Clot risk is more than forum folklore. The label warns about blood clots, particularly with immobility, and fatal stroke in susceptible postmenopausal women. Those populations do not provide a personal risk estimate for male users. Raloxifene hydrochloride tablets — DailyMed prescribing information (Official context · Accessed 2026-09-30)
Foot rashes persisted after stopping. RoidyNoob reported they were fading, but had not disappeared. Raloxifene & Gyno. My experience. Log — RoidyNoob (Personal report · Accessed 2026-09-30)
Months can pass without a noticeable response. sheker_03 felt neither benefit nor side effects after three months. Older discussion also describes no noticeable feeling or mood and hot-flash complaints during weeks 1–4. Feeling a drug is not evidence that a lump is shrinking. My gyno experience: Raloxifene did not work, on Tamoxifen for 1 month — sheker_03 (Personal report · Accessed 2026-09-30)
Medical restrictions extend beyond gyno. The label contraindicates pregnancy and prior clots; warfarin, cholestyramine and systemic estrogen need interaction review. It provides no male indication. Lipid changes do not establish heart protection. Raloxifene hydrochloride tablets — DailyMed prescribing information (Official context · Accessed 2026-09-30)
Source context — Raloxifene hydrochloride tablets — DailyMed prescribing information: Official label context; risks and Table 3 population are predominantly postmenopausal women. Not community doses, proof of male gyno response or a male individualized risk estimate. All label mirrors/reprints belong to this one source origin; prose allocation recorded below.
Source context — Raloxifene & Gyno. My experience. Log — RoidyNoob: One retrospective account following anabolic steroids and other PCT drugs; subjective improvement. Quoted duplicates are the same author, not corroboration. Later page 4 retrieval failed, so no later durability is claimed. Source family is this original forum post.
Source context — My gyno experience: Raloxifene did not work, on Tamoxifen for 1 month — sheker_03: One account; bupropion discontinued with tamoxifen initiation. Later improvements and stopping outcome belong to tamoxifen, not raloxifene. No causal comparison.
Full notes
Raloxifene, also called Evista or ralox, is an oral selective estrogen-receptor modulator (SERM). Bodybuilding discussions focus on gyno: breast lumps, tenderness and puffy nipples. Accounts range from noticeable improvement to no change or worsening, and an improvement while taking it may not last after stopping.
What raloxifene actually does
- It changes estrogen's action at receptors. A SERM can block estrogen signals in some tissues and support them in others. Raloxifene's breast effects explain the gyno interest; it is not an aromatase inhibitor (AI) that prevents estrogen production. Official context Community
- Gyno treatment and PCT are different goals. Post-cycle therapy (PCT) means attempts to recover hormone function after anabolic steroids. The familiar ralox-for-gyno, tamoxifen-for-PCT comparison is community shorthand, not proof that raloxifene substitutes for a complete recovery assessment. Tamoxifen is also called Nolvadex or nolva. Community Reddit r/gynecomastia
- Tablets, not a peptide injection. The discussion concerns oral tablets, commonly described as 60 mg. They require no reconstitution. A puffy appearance, a painful nipple and a palpable lump are different things that posters may group together as gyno. Community Personal report Personal report
Benefits people hope for
- Less puffiness and a smaller-feeling lump. S1ngleBarre1 described much smaller lumps and almost no puffiness by day 26, despite an eight-year history after steroid use. Their estimate of roughly 75% reduction was personal judgment, not a scan or measured gland volume. Personal report
- Appearance and tenderness can move differently. Cultural-Can-3394 described a smaller left-sided lump after two weeks at 120 mg/day, but continued sensitivity. Relief of one feature does not establish that the whole problem has resolved. Personal report
- A less disruptive experience than tamoxifen, for some. One steroid-cycle commenter described slower improvement with raloxifene and almost no side effects, while tamoxifen brought libido, joint and vision complaints. Another author found raloxifene ineffective. These are different people, not a reliable ranking of the two drugs. Reddit r/gynecomastia Personal report
Doses people discuss
Amounts in accounts, not a personal regimen.
- 60 mg/day orally is a recurring amount. It appears in both the improvement account and the unsuccessful pubertal-gyno account. Daily total and tablet strength are separate concepts; the same reported amount produced different experiences. Personal report Reddit r/gynecomastia
- 30 mg reductions and 120 mg/day also appear. The positive poster planned a later 30 mg/day reduction. A separate account reported 120 mg/day for two weeks. Older notes mention splitting and 60–120 mg amounts without a clear interval; those ambiguous mentions do not establish 120 mg per administration or an escalation rule. Personal report Personal report Community
Half-life and what the reports can tell us
- Days-long presence is circulated shorthand. The community record describes lingering SERM presence, but these accounts do not measure how quickly blood levels halve. Feeling nothing, or noticing nipple changes after a week off, cannot supply a bodily half-life or a safe spacing rule. Community Personal report Reddit r/gynecomastia
When people notice something
- Some report changes within days or weeks. A reply in the positive thread described one side improving by day four while the other lagged. The main author reported improvement by day 26; the 120 mg/day account reported a change by two weeks. These are report checkpoints, not a guaranteed starting day. Personal report Personal report
- Months can pass without a noticeable response. sheker_03 felt neither benefit nor side effects after three months. Older discussion also describes no noticeable feeling or mood and hot-flash complaints during weeks 1–4. Feeling a drug is not evidence that a lump is shrinking. Personal report Community
What lasts during and after use
- No predictable single-tablet effect window. Posts track breast appearance across repeated use, rather than an hours-long felt effect. They do not establish how long one tablet controls tenderness or growth. Personal report Personal report
- Worsening after a week off. hellloitsme69 described clearer worsening after stopping, following increased puffiness during use. This does not establish a typical recurrence window. Reddit r/gynecomastia
- Improvement still present two months off. That was RoidyNoob's follow-up snapshot, not permanent reversal. Personal report
Course lengths and stopping discussions
- Weeks to months, with no agreed course. The positive poster planned 55 days at 60 mg/day followed by ten days at 30 mg/day; a finished outcome was not documented. The nonresponder had already taken it for three months. Personal report Personal report
- Six months is another history, not a minimum. That was RoidyNoob's reported course. Personal report
- No established repeat calendar or protective taper. Stopping accounts do not establish a required break or dependable rebound-prevention method. The weeks-long folklore is not a lifelong maintenance claim. Community Reddit r/gynecomastia
Cautions that matter
- Clot risk is more than forum folklore. The label warns about blood clots, particularly with immobility, and fatal stroke in susceptible postmenopausal women. Those populations do not provide a personal risk estimate for male users. Official context Community
- Foot rashes persisted after stopping. RoidyNoob reported they were fading, but had not disappeared. Personal report
- Other medicines complicate interpretation. hCG and enclomiphene occur in PCT combinations, while heavy AI use adds another hormone change. Such combinations cannot isolate raloxifene's contribution. Community
- Medical restrictions extend beyond gyno. The label contraindicates pregnancy and prior clots; warfarin, cholestyramine and systemic estrogen need interaction review. It provides no male indication. Lipid changes do not establish heart protection. Official context
What the accounts reveal
- Smaller does not always mean less sensitive. The two-week account still described sensitivity despite a smaller-feeling lump. Changes in touch, appearance and discomfort deserve separate attention. Personal report
- A switch is not a controlled comparison. After three months without a raloxifene response, sheker_03 reported improvement on tamoxifen alongside severe low mood, fatigue and poor concentration. Stopping bupropion occurred at the same time. Later replies describe better tolerance after reducing tamoxifen and no returning growth one month after stopping it; these are tamoxifen follow-ups, not durable raloxifene results. Personal report
- Worsening is part of the record too. hellloitsme69 felt nipple activity but saw more puffiness while taking raloxifene, then worsening after stopping and improvement after returning to tamoxifen. They questioned product quality and individual response. Neither explanation was verified, and feeling activity was not an early success signal. Reddit r/gynecomastia
Separately labeled medical timing context
- Label half-life: 27.7 hours after a single dose; 32.5 hours with repeated dosing. These means come from pharmacokinetic data in healthy postmenopausal women, not community measurements or a gyno-effect duration. The approved 60 mg/day indications concern postmenopausal osteoporosis and breast-cancer risk reduction, not male gyno. Official context